Start free
Workflows

Standard of care evolution

Pick the patients for your first pivotal trial: Sleuth maps today’s standard of care line by line, dates every readout that could change it before you launch, and redraws the market for each result.

Run Standard of care evolution

In Studio: Standard of Care Evolution

Use it when

  • You lead clinical strategy, or you're the CEO, with an early asset and a first pivotal trial to design.
  • You need to know which line of therapy and which patients give you the best start, given what could change before launch.
  • You're building a forecast and need patients and time on treatment by line in your launch year.

What to have ready

What your asset has shown, the edge you expect, the decision you face, and the markets and year you expect to launch.

How it runs

  1. Describe your asset. Its data so far, its edge, and your launch markets and year.
  2. Decide what counts. Choose how to rank each patient group, such as the result to beat, patient numbers, time to readout, and competition, and how much each one counts.
  3. Shape the plan. Sleuth shows its three steps: map today's standard of care, find what could change it, and project where your asset should start. Add a trial to watch before it runs.
  4. Get the analysis. The patient groups ranked for your first pivotal trial, the readouts that could change the order, and the market map as a dataset.

What you get

Your questionWhat Sleuth gives you
What's the standard today, and the bar in each line?Each line of therapy and patient group, with its standard regimen, the result to beat, how many patients there are, and how long they stay on treatment.
What could change it before we launch?Every late-stage trial that could change a standard by your launch year, with its comparator, its eligibility, and a dated readout, including your own next data.
Where should we start if each readout goes either way?The market redrawn for each result, and the patient groups ranked for your first pivotal trial, with what would change the order.

A finished example

Where should a CDK2 inhibitor's first pivotal trial start? After a CDK4/6 inhibitor. The HR+/HER2-negative breast cancer market of 2031, redrawn for 25 readouts. Second line stays first unless the 2028 class readouts or the drug's Phase 1b fail. See the full example

Questions

Can I use it for a forecast?

Yes. The map sizes the patients and the time on treatment in each line for your launch year, which is where a forecast starts.

How are readouts dated?

From company guidance or the FDA where there is one, and from the trial registry or other sources where there isn't. The map marks which is which.

Does it count our own next readout?

Yes. Your next data, such as a Phase 1b, goes on the timeline with every other readout, and the ranking shows where you'd start if it fails.

Which markets does it cover?

The markets you choose. The example maps the U.S.

Does it cover every line of therapy?

Yes. Each line and patient group gets its own standard, benchmark, and patient numbers, including the groups today's pivotal trials left out.

Credits

The plan shows the size of the job before anything runs: rows times analytical columns is the credits it will use. How credits work

Next questions on the same project

Pharma partnering finds who to partner with for the first line. Asset assessment prices an asset against the same market. Graveyard analysis shows what ended the drugs before yours.